Status:
RECRUITING
Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
Lead Sponsor:
Peking University Third Hospital
Collaborating Sponsors:
Beijing Geriatric Hospital
Conditions:
Pulmonary TB
Eligibility:
MALE
25-60 years
Brief Summary
This prospective study aims to determine the incidence of Post-tuberculosis lung damage (PTLD), examine trends in the changes in lung function, and investigate the impact of smoking and other factors ...
Detailed Description
Introduction: Post-tuberculosis lung damage (PTLD) refers to residual pulmonary impairment following the completion of tuberculosis (TB) treatment, characterized by persistent respiratory symptoms and...
Eligibility Criteria
Inclusion
- Male patients aged 25-60 years newly diagnosed with active pulmonary TB.
Exclusion
- patients with positive sputum smear or TB culture results;
- human immunodeficiency virus-positive patients;
- patients infected with multidrug-resistant TB;
- patients with malignant neoplasms (e.g., lung cancer) or severe cardiovascular and cerebrovascular diseases;
- non-compliant patients who were unable to complete the lung function tests;
- patients without lung parenchymal destruction (such as tuberculous pleurisy). -
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT05426720
Start Date
January 1 2022
End Date
December 31 2027
Last Update
June 22 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, China, 100191
2
Beijing Geriatric Hospital
Beijing, China